Cytoprotective Drugs and Helicobacter pylori Infection

  • M. Del Tacca
  • G. Natale
  • C. Blandizzi
Conference paper


Cytoprotection has been defined as the ability of pharmacological agents, originally prostaglandins (PGs), to prevent or reduce gastric or intestinal mucosal injury produced by a variety of ulcerogenic and necrotizing agents, including ethanol, nonsteroidal anti inflammatory drugs (NSAIDs), steroids, bile and Helicobacter pylori (HP; Fig. 1). Gastric mucus plays an important role in maintaining or restoring gastroduodenal mucosal integrity because, other than acting as a physical barrier, mucus may create an unstirred layer of secreted bicarbonate and hence help to neutralize hydrogen ions.


Gastric Mucosa Pylorus Infection Drug Invest Unstirred Layer Gastric Mucus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Barbara L, Biasco G, Capurso L, Dobrilla G, Lalli A, Paganelli GM, Pallone F, Torsoli A (1990) Effects of sucralfate and sulglycotide treatment on active gastritis and Helicobacter pylori colonization of the gastric mucosa in non-ulcer dyspepsia patients. Am J Gastroenterol 85:1109–1113PubMedGoogle Scholar
  2. 2.
    Bernardini MC, Blandizzi C, Morini G, Chiavarini M, Impicciatore M, Del Tacca M (1989) Pirenzepine prevents cysteamine-induced formation of gastroduodenal ulcers and reduction of mesenteric circulation. Arch Int Pharmacodyn Ther 302:242–254PubMedGoogle Scholar
  3. 3.
    Berstad A, Alexander B, Weberg R, Serck-Hanssen A, Holland S, Hirschowitz BI (1988) Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. Gastroenterology 95:619–624PubMedGoogle Scholar
  4. 4.
    Blandizzi C, Gherardi G, Marveggio C, Del Tacca M (1991) Omeprazole-induced protection against experimental gastric ulceration is mediated by an increase in mucus secretion. Digestion 49(S1): 14Google Scholar
  5. 5.
    Cave DR, Vargas M (1989) Effect of a Campylobacter pylori protein on acid secretion by parietal cells. Lancet ii: 187–189CrossRefGoogle Scholar
  6. 6.
    Chen XG, Correa P, Offerhaus J, Rodriguez E, Janney F, Hoffmann E, Fox J, Hunter F, Diavohtsis S (1986) Ultrastructure of the gastric mucosa harboringCampylobacter-like organisms. Am J Clin Pathol 86:575–582PubMedGoogle Scholar
  7. 7.
    Fukuda T, Kimura S, Arakawa T (1990) Possible role of leukotrienes in gastritis associated with Campylobacter pylori. J Chn Gastroenterol 12:S131-S134CrossRefGoogle Scholar
  8. 8.
    Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT, Sweeney EC, O’Morain C (1988) Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut 29:279–283PubMedCrossRefGoogle Scholar
  9. 9.
    Jones DM, Eldridge JA, Sethi P, Whorrell PJ (1986) Antibody to the gastric Campylobacter-likc organisms Campylobacter pyloridis clinical correlation and distribution in the normal population. J Med Microbiol 22:57–66PubMedCrossRefGoogle Scholar
  10. 10.
    Kobayashi K, Arakawa T, Nakamura H (1990) An experimental model for evaluating the protective effects of antiulcer drugs. Drug Invest 2(1): 10–12Google Scholar
  11. 11.
    Konturek SJ, Bilski J, Kwiecien N, Obtulowicz W, Kopp B, Oleksy J (1987) De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin-dependent mechanism. Gut 28:1557–1563PubMedCrossRefGoogle Scholar
  12. 12.
    Kuwayama H, Matsuo Y, Eastwood GL (1990) Gastroduodenal mucosal injury by nonsteroidal anti-inflammatory drugs. Drug Invest 2(1): 22–26Google Scholar
  13. 13.
    Lambert JR (1990) Effect of antiulcer drugs onHelicobacter pylori. Drug Invest 2(1): 52–55Google Scholar
  14. 14.
    Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR (1988) Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol 26:93–99PubMedCrossRefGoogle Scholar
  15. 15.
    Morley J, Bray MA, Jones RW (1979) Prostaglandin and thromboxane production by human and guinea pig macrophages and leucocytes. Prostaglandins 17:730–736CrossRefGoogle Scholar
  16. 16.
    Nakajima M, Tanaka N, Kuwayama H (1990) Digestion of human gastric mucus by extracellular enzymes oi Helicobacter pylori. Drug Invest 2(1): 60–62Google Scholar
  17. 17.
    Parodi MC, Marugo M, Ciancamerla G, Santucci R, Fazzuoli L (1990) Prostaglandin E2 and F levels in the duodenal and antral mucosa of non-ulcer dyspeptic and duodenal ulcer patients. Hepatogastroenterology 37:208–211PubMedGoogle Scholar
  18. 18.
    Peskar BM, Weiler H, Kroner EE, Peskar BA (1981) Release tissue of man and rat in vitro and the effect of endotoxir 21:9–14Google Scholar
  19. 19.
    Sidebotham RL, Baron JH (1990) Hypothesis:Helicobacte ulcer. Lancet 335:193–195PubMedCrossRefGoogle Scholar
  20. 20.
    Slomiany BL, Bilski J, Sarosiek J, Murty VLN, Dworkin BA (1987) Campylobacter pyloridis degrades mucin and un Biochem Biophys Res Commun 144:307–314CrossRefGoogle Scholar
  21. 21.
    Sontag SJ (1986) Prostaglandins in peptic ulcer disease: an c directions. Drugs 32:445–57PubMedCrossRefGoogle Scholar
  22. 22.
    Taha AS, Boothman P, Holland P, McKinlay A, Upadhyay R, Kelly RW, Lee F, Russell RI (1990) Gastric mucosal prostaglandin synthesis in the pi patients with gastric ulcers and non-ulcer dyspepsia. Am J Gastroenterol 85:47–50PubMedGoogle Scholar
  23. 23.
    Taha AS, Kelly RW, Gemmell CG, Lees FD, Russell Helicobacter pylori culture filtrate and indomethacin: effeci antral mucosa and its prostaglandin E2 production in vitro. Aliment Pharmacol Ther 4:265–273Google Scholar
  24. 24.
    Tarnawski A, Hollander D, Cummings D, Krause WJ, Gergely H, Zipser RD(1984) Are antacids acid neutralizers only? Histologic, ultrastructural and mucosa induced by antacids. Gastroenterology 86:1276Google Scholar
  25. 25.
    Tarnawski A, Hollander D, Stachura J, Krause WJ, Gergely H(1985) Prostaglandin protection of the gastric mucosa against alcohol injury - a dynamic time-related process. Gastoenterology 8:334–352Google Scholar
  26. 26.
    Zeidler H, Muenzel P (1989) NSAIDs: new approaches to limiting gastropathy. Scand J Rheumatol 78:18–23CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • M. Del Tacca
    • 1
  • G. Natale
    • 1
  • C. Blandizzi
    • 1
  1. 1.Institute of Medical PharmacologyUniversity of PisaPisaItaly

Personalised recommendations